SCHEMBL13152016

SCHEMBL13152016

CC(C)(C)C(=O)c1cc(Cl)cc(Cl)c1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.49
KDM4E B2RXH2 11/20 0.49
GAA P10253 10/20 0.49
GLA P06280 8/20 0.49
HPGD P15428 9/20 0.48
MAPT P10636 2/20 0.46
HSD17B10 Q99714 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 2/20 0.40
ESR2 Q92731 1/20 0.40
AKR1C4 P17516 1/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
AKR1C1 Q04828 1/20 0.40
CNR1 P21554 2/20 0.39
CNR2 P34972 2/20 0.39
CYP3A4 P08684 1/20 0.39
MEN1 O00255 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24346269 0.81 ALDH1A1 (0.49) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL23313873 0.79 AKR1C2 (0.60) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL15014131 0.79 ALDH1A1 (0.53) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL17238832 0.77 POLB (0.53) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL31355215 0.76 ALDH1A1 (0.54) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL1807629 0.76 ALDH1A1 (0.59) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL11626232 0.76 ALDH1A1 (0.54) ALDH1A1KDM4EGAAGLAHPGD
3,5-Dichloroanthranilic Acid SCHEMBL29557172 0.76 AKR1C4 (0.61) ALDH1A1KDM4EGAAGLAHPGD
SCHEMBL29791639 0.76 ALDH1A1 (0.59) ALDH1A1KDM4EGAAGLAHPGD
3,5-Dichloroanthranilic Acid SCHEMBL951092 0.76 AKR1C4 (0.61) ALDH1A1KDM4EGAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) 2017-01-19 US disclosed
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) 2017-01-19 US disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 ALDH1A1 617/4885KDM4E 3644/4885GAA 272/4885
US-20170014419-A1 MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS AGTR2, MME, AGTR1 ALDH1A1 2036/4885KDM4E 3004/4885GAA 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.